These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12383135)

  • 1. A systematic review of tegaserod for the treatment of irritable bowel syndrome.
    Jones BW; Moore DJ; Robinson SM; Song F
    J Clin Pharm Ther; 2002 Oct; 27(5):343-52. PubMed ID: 12383135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ; Frampton JE; Croom KF
    Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
    Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A
    Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials.
    Müller-Lissner S; Koch G; Talley NJ; Drossman D; Rueegg P; Dunger-Baldauf C; Lefkowitz M
    J Clin Epidemiol; 2003 Apr; 56(4):310-6. PubMed ID: 12767407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S; Berrada D; Lembo A
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: tegaserod.
    Camilleri M
    Aliment Pharmacol Ther; 2001 Mar; 15(3):277-89. PubMed ID: 11207504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
    Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
    Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod.
    Scott LJ; Perry CM
    Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.